Epi Notes by South Carolina Department of Health and Environmental Control, Bureau of Disease Control
              Vol. XXV  Issue No.  4 Fall  2005
(Continued on page 3)    (Continued on page 4)
South Carolina Influenza Surveillance
2005-06 Season
Lena M. Bretous, MD, MPH
Medical Epidemiologist
Enhanced Avian Influenza A Surveillance
The CDC and SC DHEC continue to encourage ‘enhanced’
surveillance for patients with influenza like illnesses (ILI)
who are at increased risk for avian influenza A.  Risk
patients include those with recent travel history, within 10
days of respiratory symptom onset, to an H5N1 affected
country.  The medical community needs to maintain
vigilance in the clinical setting and consider the following
actions:
1) Consistently obtain international travel history and
other exposure risk information for persons with the
following symptoms and circumstances:
- Fever of >38C
- One of more of the following: cough, sore
throat, shortness of breath
- History of contact with poultry, suspected or
known human case in an H5N1 affected
country.
2) Obtain rapid diagnostic laboratory tests for patients
who are at risk for avian influenza
3) Rapidly implement infection control measures, as
listed on the CDC website.
4) Immediately report the suspected case to the local
health department for consultation and assistance
in obtaining the appropriate testing.  Please note that
all suspected cases of human avian influenza must
be reported to the local health department, which
then consults with CDC.
Current Status of Confirmed Human Avian Influenza A
Cases Reported to the WHO
According to the WHO (World Health Organization), as of
September 19, 2005, the cumulative number of confirmed
human cases of avian influenza A (H5N1) are:  91 in Viet
Nam, 17 in Thailand, four in Cambodia and two in Indonesia.
Immunization Update
Jesse E. Greene, MSN, RN, Director
DHEC Immunization Division
Influenza Vaccines
News of FDA’s licensing of GlaxoSmithKline’s (GSK)
influenza vaccine and the company’s announcement to
sell about 8 million doses in the U.S. this season, coupled
with Sanofi pasteur’s 50 to 60 mill ion doses and
MedImmune’s 3 million doses of FluMist, has produced
a brighter outlook for the national
Influenza vaccine supply for the
2005-06 season.  If Chiron secures
FDA approval, company officials
indicate they plan to produce 18
26 million doses for use in the U.S.
(Continued on page 2 )
MedImmune still has quantities of
its FluMist available for pre-
booking and Sanofi Pasteur
continues to pre-book orders for its
pediatric influenza vaccine in the
pre-filled syringes.  Distributors
for the influenza vaccines produced
by Chiron and GSK have been
taking orders for those products as
follows:  FFF -800-843-7477,
McKesson 1-800-446-3008.  Other
distributors include PSS Caligore,
GIV, ASD, Priority, and
Seacoast.
Update on Tuberculosis in South Carolina
Eric R. Brenner, MD
Rick Ervin, MD
Abstract - This issue of Epi Notes includes two articles
about tuberculosis (TB) in South Carolina.  This article
presents a general update about epidemiologic trends
and TB control in the state, along with lists of additional
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The Prevention and Control of Influenza, recommendations
of the Advisory Committee on Immunization Practices (ACIP)
were published in the Morbidity and Mortality Weekly Report
(MMWR) on July 29, 2005.  The entire document may be
found on the following website:
www.cdc.gov/mmwr/preview/mmwrhtml/rr5408a1.htm
Persons at increased risk for influenza
complications are again the focus of this year’s
influenza vaccination strategy.  Influenza vaccine
is being distributed to providers’ offices.  Please
note that the live attenuated influenza vaccine
(LAIV) FluMist™ cannot be stored in a dorm-style
refrigerator.
On September 2, 2005, CDC announced, “Given
the uncertainties in doses and distribution, CDC
recommends that the following priority groups
receive inactivated influenza vaccine until October
24, 2005.  Beginning October 24, 2005, all persons
will be eligible for vaccination”.  This document
may be found on the following website:
h t tp : / /www.cdc .gov /mmwr /p rev iew/mmwrh tml /
mm5434a4.htm
• Persons aged 65 and older, with and without
        chronic health conditions
• Residents of long-term care facilities
• Persons aged 2-64 years with chronic health
        conditions
• Children aged 6-23 months
• Pregnant women
• Health-care personnel who provide direct
        patient care
• Household contacts and out-of-home
        caregivers of children aged <6 months
It should be noted that vaccination with the live, nasal-spray
flu vaccine (FluMist™) is always an option for healthy
persons aged 5-49 years who are not pregnant.  This
vaccine is not subject to prioritization and can be given to
healthy 5-49 year olds at any time.
Meningococcal Vaccines
In January 2005, a tetravalent meningococcal
polysaccharide-protein conjugate vaccine MCV4, trade
name Menactra™ manufactured by Sanofi Pasteur, Inc.,
was licensed for use among persons aged 11 – 55 years.
The Centers for Disease Control and Prevention (CDC)
published revised recommendations of the Advisory
Committee on Immunization Practices (ACIP) regarding
the Prevention and Control of Meningococcal Disease  http://
www.cdc.gov/mmwr/PDF/rr/rr5407.pdf on May 27, 2005.
Due to rapid increase in demand for this vaccine, the
manufacturer has introduced order limits in both the public
and private sectors.  As a result, CDC placed caps on
monthly MCV4 allocations to states.  These allocations
will be relaxed as the manufacturer increases production
of MCV4.  Therefore, during initial implementation of this
new vaccine, vaccine providers are reminded that the
recommendations for the routine vaccination of
adolescents with MCV4 prioritize:
1. Adolescents at the 11- to 12-year health-care visit, and
2. Adolescents prior to high school entry (approximately
aged 15 years), if they have not previously received
MCV4.
Routine vaccination is also recommended for certain
persons who have increased risk for meningococcal
disease.  Use of MCV4 is preferred among persons aged
11 – 55 years; however, use of tetravalent polysaccharide
vaccine (MPSV4) is recommended among children aged
2 – 10 years and persons aged >55 years.  If MCV4 is
unavailable, MPSV4 is an acceptable alternative for
persons 11 – 55 years.
The following persons are at increased risk for
meningococcal disease:
•   College freshmen living in dormitories
•    Microbiologists who are routinely exposed to isolates of
     N. meningitidis
•    Military recruits
•    Persons who travel to or reside in countries in which N.
     meningitidis is hyperendemic or epidemic, particularly
     if contact with the local population will be prolonged
•    Persons who have terminal complement component
     deficiencies
•    Persons who have anatomic or functional asplenia
Due to both federal and state funding deficits, DHEC
implemented meningococcal vaccines through the S.C.
Vaccine Assurance For All Children (VAFAC) Immunization
Partnership as VFC-only.  This means that VAFAC providers
may order meningococcal vaccines for those children and
adolescents under age 19 years, for whom the vaccine is
recommended by ACIP and prioritized in the descriptions
above, and who are either Medicaid enrolled, Uninsured
(no insurance), American Indian or Alaskan Native.
Additionally, the Under-insured (insurance plan does NOT
cover the vaccine) are VFC-eligible if vaccinated in
Federally Qualified Health Centers (FQHC) or Rural Health
Clinics (RHC).
For additional information contact the DHEC Immunization
Division at 1-800-277-4687.
Antiviral Drugs for Prophylaxis and
Treatment of Influenza
Shirley Jankelovich, MD,
Medical Epidemiologist
At this time, there are no significant changes in CDC
recommendations for the use of anitvirals for prophylaxis
and treatment of influenza.  The latest guidance is
published in the MMWR “Prevention and Control of
Influenza”, July 29, 2005, Vol 54, RR-8.  This document
may be found at http://www.cdc.gov/mmwr/preview/
mmwrhtml/rr5408a1.htm.
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Reporting of Streptococcus Pneumoniae,
Invasive Disease
Amy E. Belflower, MSPH
Surveillance and Quality Assurance Epidemiologist
Prior to the year 2000, 60,000 cases of invasive S.
pneumoniae were reported in the U.S. each year with 40%
of these infections being non-susceptible (intermediate
susceptibility or resistant) to at least one antibiotic.  By
2002, the number of annual cases of S. pneumoniae
decreased to 37,000 reported cases due to the introduction
of the pneumococcal conjugate vaccine for children.
However, 34% of these infections were sti l l non-
susceptible to at least one antibiotic and 17% were
resistant to three or more antibiotics.  Data from the CDC
Active Bacterial Core Surveillance (ABCs) Report for 2003
shows national resistance percentages for various
antibiotics to invasive S. pneumoniae as follows:
• 17.3% of cases were resistant to erythromycin
• 17.0% to TMP/Sulfa
• 9.8% to penicillin
• 5.7% to tetracycline
• 0.8% to cefotaxime
• 0.3% to levofloxacin (CDC)
The current 2005 South Carolina List of Reportable
Conditions identifies Invasive Streptococcus pneumoniae
as reportable within 7 days to SC DHEC.  Reporting of
antibiotic resistance patterns is also requested for all
cases.  Currently, analysis of reportable disease data from
our Carolinas Health Electronic Surveillance System
(CHESS) shows that only 33% of S. pneumoniae reports
in SC include antibiotic resistance information.  For
national surveillance and monitoring purposes, it is
There have been a total of 59 confirmed deaths reported
to the WHO.
It is likely that influenza A (H5N1) infection among birds
has become endemic to the Asian region and that human
infections will continue to occur. So far, no sustained
human-to-human transmission of the influenza A (H5N1)
virus has been identified, and no influenza A (H5N1)
viruses containing both human and avian influenza virus
genes, indicative of gene reassortment, have been
detected.
Influenza Culture Laboratory Surveillance
Influenza laboratory surveillance will be the same as last
year.  The DHEC Bureau of Laboratories will continue to
provide influenza culture testing kits to providers and
laboratories already enrolled in the laboratory surveillance
network.  If you would like to participate in the influenza
culture laboratory surveillance network, please contact Dr.
Jennifer Meredith in the DHEC Bureau of Laboratories at
803-896-0870.
Positive Rapid Influenza Test Surveillance
SC influenza rapid test reporting requirements are the
same this year as they were last year.  Positive rapid
antigen test results may be reported by summary numbers
of positive rapid test results and type of influenza (A, B or A/
B) that the test detects.  No specific patient information is
needed.  The health care provider may still use the DHEC
Disease Reporting Cards to report summary numbers of
positive rapid tests OR a weekly summary worksheet
provided by your local health department.  These weekly
summary sheets may be faxed or emailed at the end of
every week to your local health department. Please note,
reporting positive rapid antigen tests by summary number
does not replace the mandatory reporting of positive
influenza viral cultures by name with other personally
identified information on the Disease Reporting Card to
DHEC.  Last year there was some confusion about
reporting positive cultures to DHEC if the specimen was
processed at the DHEC Bureau of Laboratories.  Please
continue to report positive influenza culture tests to your
local health department via the DHEC Disease Reporting
Cards or phone, even if the specimen was processed at a
DHEC lab.  The DHEC Bureau of Laboratories does not
report positive culture specimens to local health
departments.  For positive rapid antigen summary
worksheets, please contact your local health department.
Influenza-Like Illness (ILI) Sentinel Surveillance
ILI Sentinel Provider Surveillance is a surveillance network
comprised of volunteer providers from internal medicine,
family practice, emergency medicine, OB/GYN, and
university health center practices.  Enrolled providers
receive work folder packets and submit weekly reports to
CDC via Internet or fax.  Submitted reports consist of
numbers of ILI patients seen out of the total number of
patients seen in a week.  ILI cases are only counted in the
absence of other known causes of illness.  No influenza
culture is required for reporting ILI cases.  Enrolled
providers receive complimentary subscriptions to the
MMRW weekly and the Emerging Infectious Diseases
Journal.  To enroll in the ILI Sentinel Provider network,
contact your local health department and please specify
‘ILI’ surveillance.
Pediatric Influenza-related deaths surveillance
Beginning in 2005, pediatric influenza-related deaths of
children up to 17 years of age was made a nationally
notifiable disease and mandated as reportable to SC
DHEC.  Physicians are to report such deaths to their local
health department.  Information required will include
previous medical history, clinical history, laboratory
influenza testing results (both positive and negative), site
of medical care (inpatient or outpatient), and history of
current influenza vaccine status.
Resources for latest information on Avian Influenza:
WHO site: http://www.who.int/csr/disease/avianinfluenza/en/
CDC Avian Influenza site:
     http://www.cdc.gov/flu/avian/index.htm
Resources for latest information on SC Influenza Activity and
Surveillance:
DHEC Influenza website:
     http://www.scdhec.gov/health/disease/acute/flu.htm
DHEC Health Alert Network:
     http://www.scdhec.gov/health/disease/han/notifications.htm
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resources and references.  The companion article
presents and explains a change in DHEC's policy
regarding tuberculin testing for persons at low risk for TB.
TB is not spread uniformly throughout the state.   In 2004
eight counties reported more than 10 cases (York,
Charleston, Richland, Florence, Horry, Berkeley, Greenville
and Beaufort) while 7 counties did not report a single case
(Abbeville, Barnwell, Fairfield, McCormick, Pickens,
Saluda, and Union.)  More detailed information regarding
TB cases and case rates by county are available at the
DHEC web site (4).  Similarly, in 2004 TB was more
common in men than in women (157 vs. 76 cases), in
blacks than in whites (141 vs.73 cases [+ 19 cases in
Asians]) and in adults than in children under age 18 (215
vs. 18 cases).  The relative rarity of TB in children (figure 2)
indicates that TB is generally well controlled in South
Carolina and that most cases currently diagnosed are the
result of transmission that occurred years or even decades
ago.
TB in the Foreign Born:  In South Carolina in 2004, TB was
diagnosed in 59 persons (25% of total cases) who were
born in other countries.  The most common countries of
origin for these were Mexico (22 cases), the Philippines
(10 cases), and Honduras (8 cases).  As TB continues to
decrease in the native-born population, it is likely that TB
in the foreign-born will progressively account for an ever
greater proportion of cases diagnosed in the state.  This
is consistent with national trends, as in the United States
as a whole over 50% of TB cases are now diagnosed
among the foreign-born.  Despite the national picture and
a slow increase in TB disease in the foreign-born in SC,
tuberculosis remains primarily a disease of our minority
populations.
TB and HIV:  As was recognized in the 1980s at the very
beginning of the AIDS epidemic, co-infection with HIV and
M. tuberculosis spells “double-trouble”.   Patients whose
cell-mediated immune system have been weakened by
HIV and are co-infected with M. tuberculosis are at
extraordinarily high risk of progressing from latent TB
infection (LTBI) to active TB disease.  While the risk of
progression from asymptomatic LTBI to disease is ~10%
over the lifetime of persons with “normal” immune systems,
this risk is of the order of 10% per year for persons with
untreated HIV infection.  It thus remains essential for all
persons diagnosed with HIV infection to receive a
tuberculin skin test, preferably as soon as possible after
the diagnosis of HIV has been made!  Fortunately recent
advances in HIV anti-retroviral therapy have diminished
the impact of HIV on the epidemiology of tuberculosis.   In
2004, 196 (84%) of the 233 TB cases reported in SC cases
were tested for HIV, and of these, 11 (6%) were found to be
co-infected.  Simultaneous treatment of HIV and
tuberculosis is diff icult because of complex
pharmacological issues relating to tolerance, toxicity,
multiple-drug interactions and pharmacokinetics (5,6).  In
general co-treatment of TB and HIV therefore requires
referral to an expert consultant.  In 1999-2000 SC
experienced an outbreak of TB among persons infected
with HIV which required extensive efforts to contain (7-9).
Diagnostic Methods: For decades standard diagnostic
tools for diagnosing pulmonary TB (other than the chest X-
ray or other radiological imaging methods) included AFB
smears and cultures, and the tuberculin skin test (TST).
These remain important but in recent years these have
been supplemented by several newer “high-tech” methods.
For example, the DHEC mycobacteriology laboratory, which
processes approximately 9500 specimens per year, uses
fully automated liquid media incubators to culture
mycobacteria from clinical specimens, and DNA gene-
probes and High-Performance Liquid Chromotography
(HPLC) to identify M. tuberculosis and to distinguish it from
other pathogenic mycobacteria.  As a result, turnaround
time for positive culture results has been greatly reduced
in most cases.  A technical revolution also appears to be
in the making regarding the venerable TST as there are
now several FDA licensed methods to perform in-vitro
lymphocyte-based immunological assays which,
essentially, perform a tuberculin skin test in a test tube.
These methods are not currently used by DHEC because
of collection to processing time limitations, but are likely
to be used in the future as their sensitivity, specificity, utility
and cost-effectiveness in different settings is better
evaluated (10-12).
Another exciting development in mycobacteriology has
been the development of  “TB Genotyping” (commonly
called “DNA fingerprinting”).   Last year DHEC joined a
national network under which all new SC isolates of M.
tuberculosis will be genotyped.  This new tool will allow for
more refined analysis of patterns of transmission and
evaluation of TB control efforts (13).
Treatment of TB:  While many of the broad principles of
TB treatment have remained unchanged for decades (e.g.
always treat TB with at least two drugs to which the patients
organisms are likely to be susceptible; never add a single
drug to a failing regimen), many of the details continue to
evolve.  DHEC follows the most recent official guidelines
for treatment of TB in the United States that are the product
of a collaborative effort among the American Thoracic
Society, the Infectious Disease Society of America, and
the CDC (14).  Aside from detailed information regarding
treatment regimens, drug dosages, and more, the
guidelines also enunciate a basic principle that had been
widely accepted for some time in the world of TB control
but had never been so explicitly stated, namely that:  “The
responsibility for successful treatment is clearly assigned
to the public health program or private provider, not to the
patient.”   This principle follows from the fact that an
infectious TB patient who fails to take his medications
properly may infect others with consequences which may
be disastrous both from a personal and from a public
health point of view, (e.g. leading to fatal miliary or
meningeal tuberculosis in infants, or leading to a
community or institutional outbreak). This new guiding
principle thus provides a formal rationale for the use of
Directly Observed Therapy (DOT) which has been
discussed in the TB literature for many years (15) and
which has gradually emerged as the “standard of care”
towards which TB programs should aim.
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Treatment of Latent TB Infection (LTBI):  Worldwide, it is
estimated that 2 billion persons (about 1 person in 3 on
the planet!) have LTBI.   Estimates for the United States
and for South Carolina may be of the order of 10-15 million
and 120,000-200,000 respectively.  Fortunately persons
with LTBI are not ill and do not transmit M. tuberculosis to
others, and only a minority of infected persons will ever
actually develop disease and thus become potentially
infectious.  In poor countries, resources available for TB
must be used to treat persons with disease.  In the USA
and other industrialized countries, treatment of LTBI (TLTBI)
is recognized as a useful adjunctive public health tool but
is reserved in priority for certain subsets of persons with
LTBI:  most notably either (a) for infected persons at high
risk of progressing from LTBI to disease such as recent
convertors and persons with known medical risk factors
(e.g. co-infection with HIV and M. tuberculosis), or (b)
occasionally for healthy persons who though they may not
intrinsically be at high risk, nonetheless live or work in a
setting in which the consequences of their progression
from LTBI to TB disease would potentially be very serious
(e.g. for a nurse who works in a newborn nursery) and
where anticipated benefits of therapy exceed the assessed
risk of drug toxicity.
Evidence based review of regimens for TLTBI were
published by the CDC in 2003 and included a range of
options including (a) INH for either 6 or 9 months (given
either daily or twice-weekly); (b) rifampin alone for 4
months; and (c) regimens built around 2-months of rifampin
and pyrazinamide (16). The latter seemed appealing
because of their short duration, but subsequent reports
showed that their toxicity, especially in HIV-negative (!)
patients made them unacceptable (17).  In DHEC TB clinics
patients treated for LTBI most commonly receive a 6-month
course of INH given either daily or twice-weekly (and,
resources allowing, and for the highest risk patients, by
directly observed therapy).  However certain higher risk
patients are treated for 9 months, notably children and
patients co-infected with HIV.
Drug resistance: An important issue for clinicians treating
TB is the prevalence of drug resistance.  Fortunately most
M. tuberculosis isolates available from South Carolina TB
patients are found to be susceptible to INH, rifampin,
ethambutol and pyrazinamide, the most important “first-
line” TB drugs  (Table 1).  Treatment of drug-resistant TB
is complex and costly and requires treatment with 2nd line
drugs which are less efficacious, usually more toxic,
produce more side effects, and are more costly in terms of
drug cost and laboratory monitoring.
Contact Investigation: Whenever indicated, DHEC
performs an investigation of contacts surrounding newly
diagnosed cases.  These investigations can (a) uncover
other cases in the source case’s entourage, and (b) identify
contacts who were infected by the index case and who
thus need to be treated for LTBI.  Priority for investigations
includes contacts of cases of smear- and culture-positive
pulmonary tuberculosis (those most likely to have been
infectious).  Contacts to cases with forms of extra-
pulmonary tuberculosis which are not infectious (e.g. TB
osteomyelitis) would be of lower priority.  However, contacts
to a young child with any form of TB would always be
examined in the hopes of identifying the “source” of the
child’s infection.   Generally a concentric circle approach is
used in which closest (e.g. household) contacts are
examined first.  The need to proceed to wider circles of
contacts is then determined by a review of results of the
initial investigation.  Where indicated, investigations may
include not only “household contacts”, but also “work
contacts” and contacts from “leisure-time” activities.
Organization of TB Control in South Carolina: Tuberculosis
services are organized around county health departments
as well as along the lines of DHEC’s former “Health
District” and newer “Health Region” structures.  Each
county health department has one (or more) designated
lead TB public health nurse who coordinates evaluation of
suspects, care of known cases, investigation of contacts,
provision of TLTBI, and liaison with key local professionals
and institutions also involved with TB Control (e.g. hospital
infection control practitioners).   DHEC also organizes a
network of physicians who hold clinics and are responsible
for medical management of patients from each county.  Dr.
Richard Ervin of Florence currently serves as the Medical
Director for the program and oversees care in 13 counties.
Other clinicians include Drs. Richard Ballew, former
Medical Director (14 counties), Arnold Denler (8 counties),
Kathryn Arden (7 counties) Jay Prashad (2 counties), and
Lloyd Hayes (2 counties).  DHEC’s TB program in Columbia
is directed by JoAnn Palmer and includes a staff of nursing,
social work and program consultants as well as a
computerized registry of cases.
TB resources:  A variety of useful TB resources are
available to physicians, nurses and other professionals.
These include excellent web sites (18), numerous
documents from the CDC (19), and several recent
comprehensive texts (20).   With the support of the American
Lung Association - Southeast Region, DHEC also offers
an intensive 4-day “TB Today” course which is attended by
30-40 professionals at each of the two sessions given
every year.  For matters relating to an individual patient, an
entrée into the DHEC TB Control system can always be
made through the “TB Nurse” in any county health
department.  More generally, consultation about public
health or clinical matters related to TB, application for
enrollment in the “TB Today” course, or requests for a
presentation about tuberculosis (e.g. for a medical
conference) can be arranged by calling DHEC’s Division
of TB Control in Columbia at 803-898-0558.
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Figure 2
SC TB Cases by Age Group: 2004
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TB Drug Resistance in South Carolina: 2004
Isolates
Drug Tested N %
Isoniazid 162 4 (2.5)
Rifampin 162 0 (0.0)
Pyrazinamide 149 0 (0.0)
Ethambutol 162 0 (0.0)
Streptomycin 157 2 (1.3)
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Figure 1
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To PPD or Not to PPD – An Issue
Revisited On the Utility of Tuberculin
Skin Tests for Low Risk Persons
Rick Ervin, MD
JoAnn D. Palmer, BA
Eric R. Brenner, MD
A tuberculin skin test issue in 1996 - Almost 10 years ago
in these same pages we reviewed the question of whether
the 40,000 odd “routine tuberculin skin tests” (TST) which
were administered yearly to pre-school aged children in
South Carolina did or did not contribute appreciably to
tuberculosis (TB) control efforts in the state.   The review
concluded that these tests might detect about two
asymptomatic cases every year and might further prevent
one additional case from occurring during the next 80 years
or so.  As several hundred cases of tuberculosis are
diagnosed in SC every year, this suggested that routine
TSTs could not be expected to have any substantial impact
on future TB trends (1).  Accordingly, we subsequently
published new guidelines for skin testing of children in
Health Departments (2).  Briefly, these advised that children
seen in DHEC clinics did not routinely need to be skin
tested, but that skin testing was always recommended (a)
for children being evaluated for an illness compatible with
TB, (b) who were being evaluated as contacts to a recently
identified case of TB, and (c) for selected other children
with clear risk factors, for example those known to be
infected with HIV, or those from families who had
immigrated within the past 5 years from high-incidence
TB countries.
A tuberculin skin test issue in 2005 – In the last 18 months,
DHEC’s Division of TB Control has considered an issue
reminiscent to that described above: whether DHEC clinics
ought or ought not to skin test low-risk adults who may
just “walk-in-for-a-test” (self-referrals) or who may even
have been referred by a physician or employer for a
“routine skin test”.   Several difficulties have been
identified related to such tests.
• Low yield:  Most people “just dropping in” have
negative skin tests so that the yield of “positive
tests” is very low.
• Low predictive value of positive tests – The few
patients found to have positive TSTs may then
typically find themselves referred for further
evaluation with a chest x-ray and subsequently
for prescription of a course of preventive therapy
with isoniazid.  However, as the prevalence of
latent TB infection (LTBI) is low in low-risk
populations, many or most of the rare positive
tests will in fact be false-positives and thus much
of this additional “medical intervention” may serve
no personal health or public health purpose.
• Low priority activity yet time consuming for
front-line TB nurses who must focus on high-
priority activities - Current work loads for DHEC
County TB nurses are high and require a focus
on high-priority TB activities including: (a)
supervision of therapy for proven cases of
tuberculosis (often involving Directly Observed
Therapy as dictated by current standards of care);
(b) evaluation of TB suspects (e.g. persons with
fever, persistent cough, weight loss and with or
without chest x-rays already shown to be
abnormal) who need a prompt and thorough
evaluation for tuberculosis; (c) investigation of
contacts to known cases of tuberculosis where
the prevalence of TST positivity is known to be
high (of the order of 33% in DHEC investigations);
(d) supervision of treatment of latent TB infection
for high-risk infected persons (e.g. infected
contacts;  persons co-infected with HIV and M.
tuberculosis, etc.)  In this setting provision of TB
services to persons who are not cases, not
suspects, and not contacts is problematic and
detracts from the  high-priority TB control activities
listed above.
• Declining resources available for public health
at the local level – As listed above, the rationales
for needing to reduce testing of low-risk persons
are epidemiologic, bio-statistical, and
programmatic considerations which also reflect
the need to emphasize “best practices”.   An
additional reality is that county health departments
currently lack the funding and staffing resources
that were available only a few years ago, and this
provides yet another reason for the need to reduce
“low-yield” / “low-priority” activities.
Guidelines for DHEC practice – When persons present to
DHEC clinics requesting a TST, staff should initially
proceed not with a TST, but rather with a “risk assessment”
which includes questions about medical risk factors (e.g.
presence of cancer, end-stage renal disease requiring
dialysis, HIV infection etc) and questions about population
risk factors (e.g. has recently lived in a homeless shelter
or jail, previously unrecognized contact to a person with
infectious TB, etc).  Persons who do not have any of these
risk factors may be educated about the matter and
discharged.  A detailed algorithm has been provided to
County Health Departments to assist them in conducting
these risk assessments.
Continued role of tuberculin skin testing – The new
guidelines notwithstanding, health departments and DHEC
TB nurses should continue to skin test: (a) all cases of TB
(who may not have been tested prior to diagnosis), (b)  all
TB suspects being evaluated for TB disease, (c) all TB
contacts being investigated, and (d) all high-risk
individuals presenting to TB clinic for any reason.  In
addition at both the county and state levels, DHEC supports
and promotes tuberculin skin testing programs as are
needed in a variety of high-risk (or potentially high-risk)
settings (e.g. hospitals, nursing homes, and prisons)
where employees and/or residents need to be skin tested
(Continued on page 8)
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as part of a comprehensive institutional TB Control
program.
A  look to the future – This new policy will be phased in
gradually.   Like other guidelines, these may be considered
“work in progress” since future changes in the
epidemiology of TB, especially at the local level, may in
the future provide rationale for change in practice.
(Note: the article “Update on Tuberculosis in South
Carolina” also presented in this issue can provide a
broader perspective in which to view the issue presented
here.)
References:
1. To PPD or Not to PPD – That is the Question.  DHEC Epi
Notes, February-March 1996.
2. Tuberculin Skin Testing of Children: New Guidelines for
Health Departments in South Carolina.  DHEC Epi Notes,
April-May 1996.
Pertussis Deaths in Infants
Shirley Jankelovich, MD,
Medical Epidemiologist
Two recent deaths in young infants in South Carolina due
to pertussis highlight the need for greater vigilance by
physicians for this disease.  In both cases, pertussis was
not recognized in the infant.  In both cases, the source of
infection was a household member in whom pertussis
was not recognized.  A recent study showed that household
members of infants with pertussis were the source of
pertussis in 75% of cases, with mothers being the most
frequent source of infection (32% of cases) (1).  Siblings,
fathers and grandparents were sources of infection in 20,
15 and 8% of cases, respectively.  In the majority of these
cases, pertussis in the household member was
unrecognized.
A very important point regarding recognition of pertussis
is that the clinical presentation of pertussis may be atypical
in many infected infants, children and adults.  Clinical
symptoms are influenced by many factors including age,
presence of antibody against pertussis (previous exposure
to pertussis, previous immunization, presence of passively
acquired maternal antibody), antibiotic administration and
concomitant infection.   For example, very young infants
may present only with a mild cough, apnea and/or hypoxia.
Infants, children and adults with antibody against pertussis
may have a brief or unrecognized catarrhal stage, absence
of a whoop, and a shorter duration of cough and no
posttussive vomiting.
Of all age groups, infants less than 4 months old are most
likely to die from pertussis (2,3).  Furthermore, the mortality
rate in these young infants has been increasing.  Of the 77
pertussis deaths reported to the CDC in the 1980’s,
infants less than 4 months old accounted for 64% of deaths.
In the 1990’s, infants accounted for 82% of the 103 deaths
reported.  High pertussis infant mortality is most likely due
to the severe complications of pertussis in this age group.
Complications include pneumonia, apnea, hypoxia,
seizures, encephalopathy and rapidly progressive
refractory pulmonary hypertension.
Physicians have a very important role in protecting these
vulnerable infants through recognition, treatment or
prophylaxis of pertussis in infants and their household
contacts.
1. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C,
Jennings CE, Rebmann CA, Gabel J, Schauer SL, Lett SM.  Infant
pertussis: who was the source? Pediatr Infect Dis J. 2004
Nov;23(11):985-9.
2. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy
TV. Trends in pertussis among infants in the United States, 1980-
1999. JAMA. 2003 Dec 10;290(22):2968-75.
 3.  Vitek CR, Pascual FB, Baughman AL, Murphy TV.  Increase in
deaths from pertussis among young infants in the United States in
the 1990s.
Pediatr Infect Dis J. 2003 Jul;22(7):628-34.
Human Lymphocytic Choriomeningitis
Virus Infection
Associated with Rodents
Marcia L. Headrick, DVM, MPH, DACVPM, FACE
Lymphocytic choriomeningitis virus (LCMV) has been
recognized as a pathogen in wild rodents, with occasional
spread to humans.  Although many LCMV-associated
human illnesses are asymptomatic or mild, severe
illnesses can occur, including neurologic damage and
death, particularly to fetuses born to infected pregnant
women, or those who have weakened immune systems.
LCMV infection in pet rodents has also been recognized,
most recently (May 2005) in relation to the fatal infection of
three of four organ transplant recipients in Rhode Island
and Massachusetts (MMWR, 54:537-9, 2005].  In their
investigation of this incident, the Centers for Disease
Control and Prevention (CDC) identified an infection rate
of approximately 3% among hamsters sampled at an Ohio
distributor that was the source of the organ donor’s pet
hamster.
In response to these findings, CDC issued Interim
Guidance for Minimizing Risk for Human LCMV Infection
Associated with Rodents [MMWR, 54: Dispatch, July 29,
2005]. The facility of the distributor was quarantined until it
can be documented as free of LCMV infection.  Traceback
efforts and records from the affected distributor did not
indicate shipment of any rodents to SC.  However,
physicians should be aware of the potential hazards
associated with pet rodents to their patients.  A Q & A type
fact sheet is available from CDC at http://www.cdc.gov/
healthypets/lcmv_rodents.htm.
(PPD cont'd from page 7)
Digitized by South Carolina State Library
Epi Notes                       Page 9                           Fall 2005
(LCMV cont'd from page 8)
Continued on page 10)
There is no definitive test for a live animal that can provide
reliable answers about its LCMV status.  Because of the
possibility that pet rodents in homes may be infected with
LCMV, CDC recommendations should be followed for pet
rodent care, including precautions for pregnant women
and persons with weakened immune systems.
Physicians should be aware that pet animals, including
rodents, can also carry other human pathogens such as
Salmonella.  Good husbandry, veterinary care, and hand-
washing are important for preventing transmission of
multiple diseases from pets to humans.
PulseNet
Julie H. Schlegel, MSPH
Foodborne Epidemiologist
The South Carolina Department of Health and
Environmental Control (DHEC) is part of a national network
of local health departments, state health departments and
federal agencies submitting data to PulseNet, a Centers
for Disease Control and Prevention (CDC) national
database of foodborne disease-causing bacteria
molecular subtypes. Molecular subtyping (or
“fingerprinting”) by pulsed-field gel electrophoresis (PFGE)
can be used to distinguish strains of organisms such as
Escherichia coli O157:H7, Salmonella, Shigella, Listeria,
or Campylobacter at the DNA level.
PulseNet plays a vital role in surveillance for and the
investigation of foodborne illness outbreaks that were
previously difficult to detect. When similar patterns are
found through PulseNet, outbreaks can be detected even
if the affected persons are geographically far apart. This
allows for a more timely and thorough outbreak
investigation and prevention of further illness.
In South Carolina, DHEC has used PulseNet data in many
outbreaks. For example, PulseNet helps us identify cases
that are linked to nationally distributed food products or
exposures. Food consumption and practices have
changed during the past 20 years in the United States. We
are observing a shift from the typical point source or “church
supper” outbreak, which is relatively easy, to detect to the
more diffuse, widespread outbreaks that occur over many
communities with only a few illnesses in each community.
Close collaboration between the private and public health
sectors is crit ical to both the foodborne outbreak
investigation process and the effectiveness of PulseNet.
Individual physicians play a vital role in alerting the public
health system about a potential foodborne outbreak by
reporting illnesses to DHEC and by collecting stool
specimens to aid in diagnosis. Laboratories play a vital
role by testing and submitting isolates to the DHEC Bureau
of Laboratories for further testing, including PFGE testing
and submission to PulseNet.
More information about the CDC’s PulseNet is available
at:
http://www.cdc.gov/pulsenet/
To report cases of reportable diseases, complete a DHEC
Disease Report Card.  For questions or consultation
regarding cases call your local county health department
or the DHEC Division of Acute Disease Epidemiology at
(803) 898-0861.
Sources:
http://www.cdc.gov/pulsenet/
Preventing Illnesses and Injuries
Associated with Animal Contact Settings
Marcia L. Headrick, DVM, MPH, DACVPM, FACE
Venues where humans and animals commonly interact
include public stables, petting zoos, traveling photo
opportunities, schools, children’s parties, livestock shows
and animal rides.  These activities normally increase in
the summer because of the general increase in outdoor
activities and family vacations/outings.  Although there is
always some risk involved when interacting with animals,
awareness of the hazards and careful behavior will
decrease the chances of turning a routine activity into a
disaster.
Although enteric bacterial i l lnesses are the most
commonly reported health risks associated with animals
in public settings, multiple other health risks are of
concern. For example, allergies can be associated with
animal dander, scales, fur, feathers, urine, and saliva.
Additional health concerns include injuries, rabies
exposures, and other infections. Both wild and domestic
animals are unpredictable and can cause serious injuries,
particularly to small children.  Also, animals infected with
enteric pathogens (e.g., E. coli O157:H7, Salmonella, and
Campylobacter) frequently exhibit no signs of illness and
may shed pathogens intermittently.
Injuries
Injuries associated with animals in public settings include
bites, kicks, falls, scratches, stings, crushing of the hands
or feet, and being pinned between the animal and a fixed
object. These injuries have been associated with multiple
species, including big cats (e.g., tigers), monkeys,
domestic animals, and zoo animals.
Infections
Multiple bacterial, viral, fungal, and parasitic agents have
been associated with animal contact. These organisms
are transmitted through various modes.  Exposure to
animal feces can result in infection with E. coli O157:H7,
Salmonella, and Campylobacter.   Infections from animal
bites are common and frequently require extensive
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treatment or hospitalization. Bacterial pathogens that are
frequently associated with animal bites include
Pasteurella,  Staphylococcus,  Streptococcus,
Capnocytophaga canimorsus, Bartonella henselae (cat-
scratch disease), and Streptobacillus moniliformis (rat-
bite fever). Certain monkey species (especially macaques)
that are kept as pets or used in public exhibitions can be
infected with herpes B virus, either asymptomatically or
with mild oral lesions. Human exposure through bites or
fluids can result in a fatal meningoencephalitis. Because
of difficulties with laboratory testing to confirm monkey
infection and high herpes B prevalence, monkey bites can
require intensive public health and medical follow-up.
Skin contact with animals in public settings might also
result in human infection. Ringworm infection caused by
Trichophyton species and Microsporum gypseum have
been documented among pet and livestock owners.
Ringworm infection in 23 persons and multiple animal
species were traced to a Microsporum canis infection in a
hand-reared zoo tiger cub. Orf virus infections (contagious
ecthyma or sore mouth) have occurred in goats and sheep
at a children’s petting zoo and in a lamb used for an Easter
photo opportunity.  In 2003, multiple cases of monkeypox
occurred among persons who had had contact with
infected prairie dogs either at a child care center or a pet
store.
Ecto- and endoparasites pose concerns when humans
and exhibit animals interact. Sarcoptes scabiei is a skin
mite that infests humans and animals, including swine,
dogs, cats, foxes, cattle, and coyotes. Although human
infestation from animal sources is usually self-limiting,
skin irritation and itching may occur for multiple days and
be difficult to diagnose. Animal fleas bite humans, which
increases the risk for infection or allergic reaction. In
addition, fleas are the intermediate host for a tapeworm
species that can infect children. Multiple other animal
helminths might infect humans through fecal-oral contact
or through contact with animals or contaminated earth.
Tuberculosis (TB) is another disease of concern in certain
animal settings. Twelve circus elephant handlers at an
exotic animal farm were infected with Mycobacterium
tuberculosis, and one handler had signs consistent with
active disease after three elephants died of TB. Medical
history and testing of the handlers indicated that the
elephants had been a probable source of exposure for the
majority of the human infections. At a zoo, seven animal
handlers who were previously negative for TB tested
positive after a Mycobacterium bovis outbreak in
rhinoceroses and monkeys.
Zoonotic pathogens may also be transmitted by direct or
indirect contact with reproductive fluids, aborted fetuses,
or newborns from infected dams. Live-birthing exhibits,
usually involving livestock (e.g., cattle, pigs, goats, or
sheep), are popular at agricultural fairs. Although the public
usually does not have direct contact with animals during
birthing, newborns and their dams are frequently available
for petting and observation afterward. Q fever (Coxiella
burnetii), leptospirosis, listeriosis, brucellosis, and
chlamydiosis are serious zoonoses that can be associated
with contact with reproductive materials.  C. burnetii is a
rickettsial organism that most frequently infects cattle,
sheep, and goats. The disease can cause abortion in
animals, but more frequently the infection is asymptomatic.
During parturition, infected animals shed substantial
numbers of organisms that might become aerosolized.
The majority of persons exposed to C. burnetii develop an
asymptomatic infection, but clinical illness can range from
an acute influenza-like il lness to l ife-threatening
endocarditis. A Q fever outbreak involving 95 confirmed
case-patients and 41 hospitalizations was linked to goats
and sheep giving birth at petting zoos. These petting zoos
were in indoor shopping malls, indicating that indoor-
birthing exhibits might pose an increased risk for Q fever
transmission.
Chlamydophila psittaci infections cause respiratory
disease (commonly called psittacosis) and are usually
acquired from psittacine birds. For example, an outbreak
of C. psittaci pneumonia occurred among the staff at a
Zoo.
Rabies Exposures
Contact with mammals may expose persons to rabies
through contamination of mucous membranes, bites,
scratches, or other wounds with infected saliva or nervous
tissue. Although no human rabies deaths caused by
animal contact in public exhibits have been recorded,
multiple rabies exposures have occurred, requiring
extensive public health investigation and medical follow-
up. Persons have received rabies postexposure
prophylaxis (PEP) after being exposed to rabid or
potentially rabid animal species (including cats, goats,
bears, sheep, ponies, and dogs) at sites including pet
stores, county fairs, petting zoos, schools, and rodeo
events. Prompt assessment and treatment are critical for
this disease, which is usually fatal.
(STREPTOCOCCUS PNEUMONIAE cont'd from page 3)
important to include antibiotic resistance to contribute to
our knowledge of the developing and dynamic antibiotic
resistance problem in the United States.  Also, due to cited
geographic variation of the prevalence of drug resistant S.
pneumoniae (CDC), it is important to gather antibiotic
resistance information for South Carolina specifically. For
questions related to reports of S. pneumoniae, please
contact your regional DHEC Public Health Office.
References:
CDC Disease Information, Drug-resistant Streptococcus
pneumoniae Disease, www.cdc.gov/ncidod/dbmd/diseaseinfo/
drugresisstreppneum_t.htm
CDC, Active Bacterial Core Surveillance (ABCs) Report, Emerging
Infections Program Network, Streptococcus pneumoniae, 2003.
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The Overwhelming Challenge of Community Associated MRSA (CA-MRSA)
George Kotchmar, MD, FAAP
Professor of Clinical Pediatrics, USC School of Medicine
Shirley Jankelevich, MD
Medical Epidemiologist, SC DHEC Divisions of Acute Disease Epidemiology and Immunizations
Dixie Roberts, MPH, RN
Director, SC DHEC Division of Acute Disease Epidemiology
Health care professionals recognize Staphylococcus aureus as an important cause of disease and understand that
antibiotic-resistant strains pose a threat to the community. No longer can methicillin resistant S. aureus (MRSA) be
regarded as an exclusive nosocomial pathogen. With community associated MRSA (CA-MRSA), resistance and virulence
have converged with a clone not seen before 2000 with molecular analysis pointing to a community origin.  Recent
2001-2004 data from the Texas Children’s Hospital revealed of the 3,586 community-associated staphylococcal
infections presenting to the Emergency Department, 2,661 were methicillin resistant (74%) with 95.9% skin and soft
tissue infections and 4.1% (110) systemic infections (osteomyelitis was the most common invasive CA-MRSA infection).
The epidemiologic definition of CA-MRSA disease is the development of infection with MRSA in the outpatient setting in
a person with a medical history who in the past year has had 1) NO admission to a hospital, nursing home, skilled
nursing facility, hospice; 2) NO dialysis or surgery; 3) NO history of MRSA infection or colonization and 3) NO permanent
indwelling catheters or medical devices that pass through the skin into the body.
Outbreaks of CA-MRSA infections have occurred primarily in persons who often have close contact and have included
prison inmates, military recruits, soldiers and crewmembers of a naval ship, players of contact sports (wrestling and
football team members), children in daycare, and men who have sex with men.
CA-MRSA and health care associated MRSA (HCA-MRSA) infections have distinct clinical differences.  While HCA-
MRSA usually cause heterogeneous invasive infections, CA-MRSA infection is usually limited to skin and soft tissue but
occasionally may be invasive.  CA-MRSA infections usually present as folliculitis, pustular lesions and furuncles/
carbuncles/ abscesses.  Many lesions are often mistaken for spider bites.  Although the CA-MRSA epidemic spans the
gamut of known skin and soft tissue infections from cellulitis to furuncles to frank abscess, a distinctive syndrome
includes rapidly progressive cellulitis.  Several invasive CA-MRSA syndromes deserve special mention, as they appear
to be novel or at least not found in the recent literature.  Necrotizing pneumonia with or without pleural empyema with
CA-MRSA strains has been implicated in a destructive pneumonitis with loss of pulmonary architecture, microabcesses,
and pulmonary vasculitis.  Although streptococcal infections are a well-known cause of necrotizing fasciitis, this syndrome
has been recently recognized as one that can be caused by CA-MRSA.  At Texas Children’s Hospital, septic
thrombophlebitis caused by CA-MRSA has been described with clinical features reminiscent of endocarditis with
sustained bacteremia and multiple embolic phenomena.  Other fulminant invasive CA-MRSA infections include
pyomyositis, osteomyelitis, arthritis, bursitis, and a new and devastating purpura fulminans syndrome.
The increased ability of CA-MRSA to spread among contacts and cause severe invasive disease is thought to be due
to a distinct cytotoxin, called Panton-Valentine leucocidin (PVL) that is not found in HCA-MRSA. CA-MRSA isolates have
a significantly different antibiotic resistance pattern from HCA-MRSA.   The most important difference is that CA-MRSA
isolates are not susceptible to B-lactam antibiotics because it harbors one of two novel methicillin-resistance cassette
gene elements called SCCmec IV or V.  However, CA-MRSA isolates are often susceptible to several non-B-lactam
antibiotics that include vancomycin, clindamycin, doxycycline, gentamycin, and trimethoprim-sulfamethoxazole (TMP/
SMX), but are frequently resistant to erythromycin and ciprofloxacin.
Currently, microbiology laboratories should routinely test S. aureus isolates for susceptibility to macrolides, clindamycin,
and trimethroprim-sulfamethazole in addition to B-lactam antibiotics.  Most CA-MRSA isolates are resistant to macrolides
but remain susceptible to clindamycin.  In vitro resistance to both erythromycin and clindamycin predicts clinical failure
with either agent.  In vitro resistance to erythromycin but susceptibility to clindamycin by routine testing may not predict
clinical effectiveness of clindamycin because of a property associated with erythromycin resistant CA-MRSA called
inducible resistance to clindamycin.  Treatment failures with clindamycin have occurred with MRSA isolates that possess
clindamycin-inducible resistance.  Clindamycin inducible resistance can be detected by a special, but simple test
called the D-test.  If this test is not available in the laboratory, the clinician should ask the laboratory unable to perform
the D-test to report MRSA strains that it determines to be resistant to erythromycin as clindamycin resistant also.
The CDC recommendations for treating CA-MRSA infections are forthcoming.  Interim recommendations are discussed
below in an algorithm (Figure 1).  In the September 2004 issue of the American Academy of Pediatrics (AAP) News
 (Continued on page 12)
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(www. aapnews.org) an expert opinion guideline is available, including an updated “Management of skin and soft
tissue infections: Principles”.
Physicians should seek information from their clinical laboratories about the prevalence of CA-MRSA outpatient infections
in their communities. Physicians should: 1) always culture purulent skin or soft tissue lesions before further management;
2) always adequately drain abscesses at presentation and send material for culture and susceptibility testing (“D”-zone
testing is necessary if erythromycin resistance and clindamycin susceptibility are reported); 3) always determine
severity of infection at presentation and need for hospitalization and empirical antimicrobial therapy; 4) always provide
discharge instructions emphasizing the need for return if no clinical improvement within 48 hours.
Outbreaks of MRSA in group settings (e.g. childcare facilities, sports teams, residential institutions, etc.) should be
reported to your local DHEC Epidemiology Office. During an outbreak, the molecular differences between CA-MRSA
and HCA-MRSA permit distinction of isolates though a specialized molecular techniques called PFGE (pulsed field gel
electrophoresis).  For certain MRSA outbreak situations, DHEC’s Division of Acute Disease Epidemiology will request
PFGE on a sample of outbreak isolates from the DHEC Bureau of Laboratories.
 For more information on prevention and control, see the CDC web site http://www.cdc.gov/ncidod/hip/ARESIST/
ca_mrsa.htm.
Specific measures to control an outbreak of CA-MRSA and for management of household contacts can be found on the
CDC website (http://www.cdc.gov/ncidod/hip/ARESIST/ca_mrsa.htm ).
In areas where MRSA accounts for more than 10% of community associated S. aureus isolates, most authorities
recommend considering modification for initial empiric therapy of severe infections most likely attributed to S. aureus.
An increasing burden of MRSA disease, especially involving clones that cause more severe invasive infections, will
have an enormous influence on the clinical approach to suspected staphylococcal infection. At a minimum, vigilance
and a decrease in the threshold for obtaining cultures to document MRSA are warranted. Although an optimal management
approach for CA-MRSA infections has not been established, the guidelines presented here represent the current view
of many authorities. Seriously ill, hospitalized patients with suspected staphylococcal infection and significant CA-
MRSA risk should be treated empirically with an antimicrobial regimen including vancomycin, with future clinical trials
determining if another agent will displace vancomycin as the drug of choice. Also, with an increase in CA-MRSA
infections, clinical trials are needed to assess the precise role of antimicrobial agents in the treatment of uncomplicated
skin and soft tissue infections, to define agents most clinically effective and cost-effective. Pending future clinical trials,
we hope these guidelines will be helpful in initiating empirical therapy for CA-MRSA infections, an identified public
health challenge growing in our community.
MRSA  REFERENCES
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C la s s if y  s e v e r i t y
S E V E R E
( in c lu d in g  to x ic ,  o r  
im m u n o c o m p ro m is e d ,  o r  l im b  
th re a te n in g  in fe c t io n ;  o r  c r i t ic a l ly  i l l)
M O D E R A T E
( fe b r i le ,  i l l  b u t
P re v io u s ly  h e a lth y )
M IL D
(a fe b r i le ,  p r e v io u s ly  h e a l th y )
·   H o s p ita l iz e
·   E m p ir ic  a n t im ic r o b ia l th e ra p y
   a g a in s t C A -M R S A
·   U s e  v a n c o m y c in  i f  c l in ic a l ly  in d ic a te d  -
   c o n s u lta t io n  w ith  a n  in fe c t io u s  d is e a s e  
   s p e c ia l is t  s h o u ld  b e  c o n s id e r e d
·   A d ju s t  th e r a p y  b a s e d  o n  c u ltu r e  a n d
   s e n s it iv i t y  r e s u lt s  a n d  c l in ic a l c o u rs e
·   H o s p ita l iz e
·   E m p ir ic  th e r a p y  in c lu d in g
   v a n c o m y c in   6
·   In fe c t io u s  d is e a s e  c o n s u lt  s h o u ld  b e
   c o n s id e re d   7
·   A d ju s t  th e r a p y  b a s e d  o n  c u l tu re  a n d
   s e n s it iv i t y  re s u lts  a n d  c l in ic a l c o u r s e
I  &  D  a lo n e  m a y
B e  a d e q u a te
·   I  &  D
·   O r a l a n t ib io tic  R x  ( fo r  C A -M R S A )
   ?  T /S   3 ,  4
   ?  C l in d a m y c in   5
   ?  D o x y c y c l in e  ( i f  >  8  y e a r s )   4
·   C lo s e  fo l lo w - u p
·  A d ju s t  th e ra p y  b a s e d  o n  c u ltu r e  a n d
  s e n s it v i t y  r e s u lt s  a n d  c l in ic a l c o u rs e
 F ig u r e  1 :  A  S u g g e s t e d  I n i t ia l  M a n a g e m e n t  A p p r o a c h  f o r  S u s p e c t e d  C o m m u n it y - A s s o c ia t e d  
M e t h ic i l lin - R e s is t a n t  S t a p h y lo c o c c u s  a u r e a u s  ( C A -M R S A )  S k in  a n d  S o f t  T is s u e  I n f e c t io n s
( C o m m u n it ie s  in  W h ic h  C A -M R S A  S t r a in s  a r e  P r e v a le n t )
1 .   If  u s in g  a n tim ic r o b ia ls
 2 .   If  a r e a  o f  in v o lv e m e n t is  e x te n s iv e ,  o r  i f  s y s te m ic   s y m p to m s  a re  c l in ic a l ly  c o n c e r n in g ,  o r  i t th e r e  a r e  c o m p l ia n c e / fo l lo w - u p
     c o n c e r n s .
3 .   T /S = t r im e th o p r im /s u lfa m e th o x a z o le
4 .   T /S  a n d  d o x y c y c l in e  a r e  n o t  r e c o m m e n d e d  t r e a tm e n ts  fo r  G r o u p  A  S te p to c o c c u s  in fe c t io n .
5 .   D o  D - te s t i f  C A - M R S A  is o la te  is  e ry th ro m y c in - re s is ta n t ,  c l in d a m y c in  s u s c e p t ib le .  T h e r e  a r e  a  s ig n i f ic a n t  n u m b e r  o f  D -te s t
     p o s i t iv e  C A -
     M R S A  is o la te s  in  S o u th  C a r o l in a .
6 .   B r o a d  e m p ir ic  th e r a p y  m a y  b e  a p p r o p r ia te ;  c o n s u lt  w ith  a n  in fe c t io u s  d is e a s e  s p e c ia l is t  s h o u ld  b e  c o n s id e r e d .   A A P  R e d
     B o o k  re c o m m e n d s  u s e  o f  n a fc il l in  +  g e n ta m ic in  in  a d d it io n  to  v a n c o m y c in  fo r  e m p ir ic  th e ra p y  o f  l i fe - th r e a te n in g  in fe c t io n s .
7 .  E x p e r ie n c e  w ith  n e w  a g e n ts  is  l im ite d , n e w  a p p l ic a t io n s  o f  o ld  a g e n ts  a r e  l im ite d ,  a n d  e x p e r ie n c e  w ith  th e s e  a g e n ts  in  c h i ld re n
    is  l im ite d .
A d d it io n a l n o te s :
·    U s e  q u in o lo n e s ,  l in e z o l id ,  d a p to m y c in ,  t ig le c y c l in e ,  o r  q u in u p r is t in - d a lfo p r is tin  (Q /D )  in  c o n s u lta tio n  w ith  a n  in fe c t io u s  d is e a s e
    s p e c ia l is t  w h e re  e x p e r ie n c e  is  l im ite d .
·    I f  in i t ia l  p a r e n te r a l  th e r a p y ,  c o n s id e r  s w itc h in g  to  o r a l  th e ra p y  b a s e d  o n  s u s c e p tib i l i t y  r e s u lts  i f  th e  p a tie n t is  a fe b r i le  fo r  2 4
    h o u r s ,  c l in ic a l ly  im p r o v e d ,  a b le  to  ta k e  o r a l  th e r a p y , a n d  c lo s e  fo l lo w -u p  is  p o s s ib le .   F o r  s e v e r e  in fe c t io n s ,  c o n s u lt  w it h  a n
    in fe c t io u s  d is e a s e  s p e c ia l is t  s h o u ld  b e  c o n s id e r e d .
·    D u ra t io n  o f t r e a tm e n t  fo r  m o s t s k in  a n d  s o f t t is s u e  in fe c t io n s  is  7 -1 0  d a y s ,  b u t  m a y  v a r y  d e p e n d in g  o n  s e v e r i ty  o f  in fe c t io n  a n d
    c l in ic a l  re s p o n s e .
·    C o n s id e r  h o s p ita l iz a t io n  fo r  in fa n ts  le s s  th a n  1  m o n th  o f a g e .
·    O b ta in  b lo o d  c u l tu r e s  o n  fe b r i le  in fa n ts  w ith  s k in  in fe c tio n , a n d  o th e r s  a s  c l in ic a l ly  in d ic a te d .
A d a p te d  f ro m  th e  M in n e s o ta  D e p a r tm e n t  o f  H e a lth  D is e a s e  C o n t ro l  N e w s le tte r ,  V o l 3 2 ,  N u m b e r  6 ,  2 0 0 4 .
( h t tp : //w w w .h e a lth .s ta te .m n .u s /d iv s / id e p c /n e w s le t te r s /d c n / in d e x .h tm l)
1
2
(CA-MRSA cont'd from page 12)
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Revised School and Childcare Exclusion Lists
Michelle L. Myer, MSN, RN, CPNP
Epidemiology and Bioterrorism Nurse Consultant
Each January SC DHEC is required to publish lists of those health conditions with which children and staff should not
attend school or out-of-home childcare settings. These Exclusion Lists, which also address attendance for individuals
exposed to certain communicable illnesses, are available on the DHEC Bureau of Disease Control’s website, at:
http://www.scdhec.gov/health/disease/exclusion.htm.
The School Exclusion List applies to most students in grades 1-12.  The Childcare Exclusion List applies to all
children in out-of-home childcare, to children in 3-, 4-, or 5-year-old kindergarten, and to medically fragile students in
grades 1-12.  For the purposes of school exclusion, “medically fragile
students” are those with special healthcare needs or developmental delays
who require close assistance with feeding or other personal hygiene activities
by which communicable illnesses may easily be spread.
The 2005-2006 School and Childcare Exclusion Lists were revised in
January 2005, as well as in January 2004.  Both revisions addressed specific
concerns raised by the 2003-2004 Lists, which had been developed from
out-of-home childcare exclusion guidance found in the 2003 Red Book.
Some changes and clarifications include:
•Exclusion standards for some conditions are now more clearly based
on age or health status of students.  For example, students six years of age
and older with pediculosis may remain at school until the end of the school
day.  Children in kindergarten or childcare must be excluded as soon as
their head lice are discovered.  For re-admission after some GI illnesses,
younger children may require negative stool cultures; while older students
may return to school once symptoms subside.
•Conditions added to the Exclusion Lists:
 o Ringworm of the Body:  Exclude for Tinea corporis that cannot be covered,
until after initiation of oral or topical antifungal treatment.  Additional exclusion
may be appropriate for some sports and physical education activities.
 o Ringworm of the Scalp:  Exclude for Tinea capitis until after initiation of
oral antifungal treatment.  Topical treatments such as selenium sulfide
shampoo (1% or 2.5%) decrease fungal shedding and may be
recommended by schools or childcare providers to help curb the spread of
infection.
•Conditions Removed.  For the School Exclusion List, symptoms such as
irritability, lethargy, and “not feeling well enough to participate in activities”
were removed, since these are not reliable indicators of communicable
illness in older students.
•Employees.  Childcare exclusion rules for staff also apply to food-handlers
working in out-of-home childcare settings.
•Both Exclusion Lists now address “Do Not Exclude” conditions such as
common colds, warts, fifth disease, pinworms and non-purulent
conjunctivitis.
•Because schools’ reporting of outbreaks greatly facilitates local and state
disease control efforts, information was added regarding mandated reporting
of those excludable conditions that appear on the SC List of Reportable
Conditions.
•Parent Brochures were developed to help parents understand when
children may need to be excluded from school or out-of-home childcare
SC Law: Children with 
contagious diseases shall not 
attend school or childcare in 
out-of-home settings. 
No superintendent, principal, 
teacher of any school or provider 
of child care in an out-of-home 
setting, as defined in S.C. Code 
Ann. Section 20-7-2700, and no 
parent, master or guardian of any 
child or minor shall permit any 
such child or minor having any 
contagious or infectious disease 
or syndrome requiring isolation to 
attend any private, parochial, 
church or Sunday school when 
the disease or syndrome of the 
child or minor is on the Official 
School and Child Care Exclusion 
List of Contagious or 
Communicable Diseases. For the 
purpose of this regulation, the 
Department of Health and 
Environmental Control shall 
publish in January of each year 
an Official School and Child 
Care Exclusion List of 
Contagious or Communicable 
Diseases, to include specific 
conditions for duration of school or 
child care exclusion and criteria 
for return for a child with any of 
these excludable diseases. 
(Regulation 61-20) 
http://www.scstatehouse.net/coder
egs/c061a.htm  
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attendance.  These brochures also address appropriate, judicious use of antibiotics.  Parent brochures, which can be
printed on legal paper for distribution to families, are found on the Exclusion List website: http://www.scdhec.gov
health/disease/exclusion.htm.
The Division of Acute Disease Epidemiology would appreciate any feedback from healthcare providers on the School
or Childcare Exclusion Lists.  These will next be revised at the end of January 2006 for the 2006-2007 school year.
Contact us at: Exclusion@dhec.sc.gov.
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Year-to-Date Summary of Reportable Conditions*
January 1, 2005  -  September 27, 2005
C O N D IT IO N  C O N F IR M E D  P R O B A B LE  T O T A L  
A s e p tic  m e nin g it is  4 1  2 1  6 2  
B a c te ria l m e ning it is , o th e r 2   2  
B ru c e llos is  1   1  
C a m p y lo b a c te rio s is  1 4 0  1  1 4 1  
C ry p to s p o rid io s is  1 4  1  1 5  
C yc lo s po r ia s is  2   2  
D e n g u e  F e ve r 1   1  
E h rlic h io s is , H um a n  g ra nu loc y tic  5  1  6  
E h rlic h io s is , H um a n  m o no c y tic  1  3  4  
E h rlic h io s is , H um a n , O th e r& un s p ec   3  3  
E n c e ph a litis ,  W es t N ile  1   1  
E n te ro he m . E .co li O 1 5 7 :H 7  6   6  
G ia rd ia s is  8 2  2  8 4  
G ro u p  A  S tre p to co c c us , in v a s ive  2 8   2 8  
G ro u p  B  S tre p to co c c us , in v a s ive  1 5   1 5  
H a e m o p h ilu s  in flu e n za e , in v as ive  2 3   2 3  
H e m o lyt ic  u re m ic  s y n d ,p o s td ia rrh e a l 2   2  
H e p a titis  A , a c ute  2 5  4  2 9  
H e p a titis  B  v iru s  in fec t io n , C h ron ic  4 0 4  7 5  4 7 9  
H e p a titis  B , a c ute  1 0 8  2 0  1 2 8  
H e p a titis  C  V irus  In fe c tio n , c h ron ic o r re s o lv ed  1 8 0 2  1 6 2 6  3 4 2 8  
H e p a titis  C , a c ute   3  3  
H TL V -I in fe c tio n  1   1  
H TL V -II  in fe c tion  1   1  
In f lu e n za , h u m an  is o la te s  5 1   5 1  
K a w a s a k i d is e as e  1  1  2  
L e g io n e llo s is  1 0  1  1 1  
L is te r io s is  1 0   1 0  
L ym e  d is e a s e  1 3  8  2 1  
M a la ria  7   7  
M u m p s  1   1  
N e is s e ria  m e n ing itid is , in va s ive  (M e n in g . d is e as e ) 1 2  1  1 3  
P e rtu ss is  2 7 7  2 7  3 0 4  
Q  fe ve r  1  1  
R o c k y M o u n ta in  s p otte d  fe ve r 1 2  4 4  5 6  
S a lm on e llo s is  8 4 3  2 4 4  1 0 8 7  
S h ig e llos is  7 6  3  7 9  
S tre p  p n e um o nia e , in v a sive  1 2 1  2  1 2 3  
S tre p to c o cc a l d is e a s e , in va s iv e , o the r 1 7   1 7  
V a n c om yc in -R e sis tan t E n te roc o cc u s  1 1 0 3  5  1 1 0 8  
V a ric e lla  (C h ic ke n p o x) 1 4 2  2 5 9  4 0 1  
Y e rs in ios is  2   2  
S c o m b ro id  fis h  p o is o n in g  2   2  
V ib r io  s p p .,  n o n-to x ig e n ic , o the r o r un s p e c ifie d  3   3  
H IV /A ID S  6 3 9   6 3 9  
TB  (n e w  c a s e s ) 1 7 7   1 7 7  
 
*T h is  re po rt do es no t inc lu de  re po rtab le  S T D  c on d itions . 
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